3817 related articles for article (PubMed ID: 7417939)
1. Anti-T antibody in malignant melanoma patients. Influence of response and survival following chemotherapy--changes in serum levels following C parvum, BCG immunization.
Thatcher N; Hashmi K; Chang J; Swindell R; Crowther D
Cancer; 1980 Sep; 46(6):1378-82. PubMed ID: 7417939
[TBL] [Abstract][Full Text] [Related]
2. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Jan; 35(1):36-44. PubMed ID: 428146
[TBL] [Abstract][Full Text] [Related]
3. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 May; 36(2):227-36. PubMed ID: 314367
[TBL] [Abstract][Full Text] [Related]
4. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
[TBL] [Abstract][Full Text] [Related]
5. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines.
Livingston PO; Kaelin K; Pinsky CM; Oettgen HF; Old LJ
Cancer; 1985 Nov; 56(9):2194-200. PubMed ID: 4052966
[TBL] [Abstract][Full Text] [Related]
6. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Jun; 36(3):456-64. PubMed ID: 487647
[TBL] [Abstract][Full Text] [Related]
7. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
[TBL] [Abstract][Full Text] [Related]
8. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
[TBL] [Abstract][Full Text] [Related]
9. Chemoimmunotherapy (DTIC and Corynebacterium parvum) for disseminated malignant melanoma.
Karakousis CP; Didolkar MS; Han T
Cancer Treat Rep; 1981; 65(9-10):925-6. PubMed ID: 7273032
[No Abstract] [Full Text] [Related]
10. Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma.
Tumori; 1984 Feb; 70(1):41-8. PubMed ID: 6369694
[TBL] [Abstract][Full Text] [Related]
11. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
Thatcher N; Crowther D
Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.
Bjornsson S; Takita H; Kuberka N; Preisler H; Catane H; Higby D; Henderson E
Cancer Treat Rep; 1978 Apr; 62(4):505-10. PubMed ID: 350388
[TBL] [Abstract][Full Text] [Related]
13. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
Clunie GJ; Gough IR; Dury M; Furnival CM; Bolton PM
Cancer; 1980 Aug; 46(3):475-9. PubMed ID: 6994866
[TBL] [Abstract][Full Text] [Related]
14. [Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU].
Kokoschka EM; Luger T; Micksche M
Onkologie; 1978 Jun; 1(3):98-103. PubMed ID: 362293
[TBL] [Abstract][Full Text] [Related]
15. Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.
Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Braun DW; Fortner JG; Oettgen HF
Cancer; 1981 Jul; 48(2):245-51. PubMed ID: 7016302
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of the non-specific resistance by Corynebacterium parvum and Bacillus calmette Guérin.
Ruitenberg EJ; Steerenberg PA
Tijdschr Diergeneeskd; 1976 Jul; 101(14):775-8. PubMed ID: 821172
[TBL] [Abstract][Full Text] [Related]
17. The natural history of resectable metastatic melanoma (Stage IVA melanoma).
Feun LG; Gutterman J; Burgess MA; Hersh EM; Mavligit G; McBride CM; Benjamin RS; Richman SP; Murphy WK; Bodey GP; Brown BW; Mountain CF; Leavens ME; Freireich EJ
Cancer; 1982 Oct; 50(8):1656-63. PubMed ID: 7116298
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of immunotherapy with BCG and Corynebacterium parvum on hepatic drug hydroxylation in man.
Wan HH; Thatcher N; Mullen PW; Smith GN; Wilkinson PM
Br J Cancer; 1979 Apr; 39(4):441-4. PubMed ID: 444399
[TBL] [Abstract][Full Text] [Related]
19. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
20. The effect of Corynebacterium parvum therapy on immunoglobulin class and IgG subclass levels in cancer patients.
James K; Clunie GJ; Woodruff MF; McBride WH; Stimson WH; Drew R; Catty D
Br J Cancer; 1975 Sep; 32(3):310-22. PubMed ID: 61040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]